#1 Clinical Trials Search in Europe

Clostridia, Cluster Xiva, Strain Relative Enterocloster Bolteae, Live

This article examines two clinical trials investigating the use of live bacterial strains for treating intestinal conditions. The first trial focuses on preventing recurrent Clostridioides difficile infection using VE303, while the second trial evaluates VE202 for treating mild to moderate ulcerative colitis. Both studies aim to assess the safety and efficacy of these novel bacterial-based therapies in addressing challenging gastrointestinal disorders.

Table of Contents

What is CLOSTRIDIA, CLUSTER XIVA, STRAIN RELATIVE ENTEROCLOSTER BOLTEAE, LIVE?

CLOSTRIDIA, CLUSTER XIVA, STRAIN RELATIVE ENTEROCLOSTER BOLTEAE, LIVE is a type of beneficial bacteria being studied as a potential treatment for certain gut-related conditions. It is part of a larger group of bacterial strains known as VE303 (for C. difficile treatment) and VE202 (for ulcerative colitis treatment)[1][2]. These treatments belong to a category called live biotherapeutic products (LBPs), which use living microorganisms to treat diseases.

How does it work?

This bacterial strain, along with others in the VE303 and VE202 formulations, is thought to work by helping restore a healthy balance of bacteria in the gut. In conditions like C. difficile infection and ulcerative colitis, the normal balance of gut bacteria is disrupted. By introducing these carefully selected beneficial bacteria, the treatment aims to:

  • Compete with harmful bacteria for resources
  • Produce substances that inhibit the growth of harmful bacteria
  • Help regulate the immune system in the gut
  • Improve the overall health of the gut lining

Treatment for C. difficile Infection

One of the main conditions being studied for treatment with this bacterial strain (as part of VE303) is Clostridioides difficile infection (CDI). CDI is a serious bacterial infection that causes severe diarrhea and can be life-threatening, especially in older adults[1].

A Phase 3 clinical trial called RestoratiVE303 is currently underway to test the effectiveness of VE303 in preventing recurrent CDI. The study aims to:

  • Compare the rate of CDI recurrence at 8 weeks between patients treated with VE303 and those given a placebo
  • Assess the safety of VE303
  • Measure how well the VE303 bacterial strains colonize the gut and how long they persist
  • Evaluate the impact on patients’ quality of life and CDI symptoms

Potential Treatment for Ulcerative Colitis

Another condition being studied for treatment with this bacterial strain (as part of VE202) is ulcerative colitis. Ulcerative colitis is a type of inflammatory bowel disease that causes inflammation and ulcers in the lining of the large intestine[2].

A Phase 2 clinical trial is currently investigating the use of VE202 in patients with mild-to-moderate ulcerative colitis. The study aims to:

  • Evaluate the effectiveness of VE202 in improving the appearance of the colon lining (endoscopic response) after 8 weeks of treatment
  • Assess the safety of VE202

How is it administered?

Both VE303 and VE202 are administered orally in the form of capsules. In the clinical trials:

  • For CDI prevention (VE303): Patients take the capsules daily for 14 consecutive days[1]
  • For ulcerative colitis treatment (VE202): Patients take the capsules for 8 weeks[2]

Safety and Side Effects

As these treatments are still in clinical trials, their full safety profile is not yet known. The ongoing studies are carefully monitoring for any side effects or adverse events. It’s important to note that these treatments use naturally occurring bacteria that are normally found in healthy human guts, which may contribute to their safety profile.

Ongoing Research

Both the VE303 and VE202 treatments are still in the research phase and are not yet approved for general use. The ongoing clinical trials will help determine their effectiveness and safety. If successful, these treatments could provide new options for patients with recurrent C. difficile infections or ulcerative colitis who have not responded well to other treatments.

It’s important to note that while these treatments show promise, more research is needed before they can be widely used. Patients interested in these treatments should speak with their healthcare providers about the possibility of participating in clinical trials or staying informed about future developments.

Aspect VE303 Trial VE202 Trial
Condition Recurrent Clostridioides difficile infection Mild to moderate ulcerative colitis
Main Objective Compare CDI recurrence rate at Week 8 Evaluate endoscopic response at Day 56
Treatment Duration 14 days 8 weeks
Age Range 12 years and older 18 to 75 years
Key Inclusion Criteria History of CDI, completion of standard antibiotic therapy Diagnosed UC for at least 3 months, active mild to moderate disease
Key Exclusion Criteria Chronic diarrhea, hypersensitivity to VE303 components History of Crohn’s disease, active infection
Primary Endpoints CDI recurrence rate, safety profile Endoscopic response rate, treatment-related adverse events

FAQ

  • What are VE303 and VE202? VE303 and VE202 are investigational drugs containing live bacterial strains. VE303 is being studied for preventing recurrent C. difficile infection, while VE202 is being evaluated for treating mild to moderate ulcerative colitis.
  • How are these drugs administered? Both VE303 and VE202 are administered orally in capsule form. In the VE303 trial, participants take the drug daily for 14 consecutive days. For VE202, participants receive the treatment for 8 weeks.
  • What are the main goals of these clinical trials? The main goals are to evaluate the safety and efficacy of these bacterial-based therapies. For VE303, the primary aim is to compare C. difficile infection recurrence rates between treatment and placebo groups. For VE202, the main objective is to assess endoscopic response and treatment-related adverse events.
  • Who can participate in these trials? The VE303 trial includes patients aged 12 and older with a history of C. difficile infection. The VE202 trial is for adults aged 18-75 with mild to moderate ulcerative colitis diagnosed at least 3 months prior to the study.
  • What are some potential benefits and risks of participating? Potential benefits include improved management of the targeted conditions. Risks may include treatment-related side effects, which are being closely monitored in both studies. It's important to note that as investigational therapies, the full range of benefits and risks is still being determined.

Ongoing Clinical Trials on Clostridia, Cluster Xiva, Strain Relative Enterocloster Bolteae, Live

  • Study on VE303 for Preventing Recurrent C. difficile Infection in Patients

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Czechia Denmark France Germany +8

  • Study on VE202 for Patients with Mild-to-Moderate Ulcerative Colitis

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia Hungary Lithuania The Netherlands Poland

Glossary

  • Clostridioides difficile infection (CDI): A bacterial infection that can cause diarrhea and serious intestinal conditions, often occurring after the use of antibiotics.
  • Ulcerative colitis: A chronic inflammatory bowel disease that causes inflammation and ulcers in the digestive tract, primarily affecting the colon and rectum.
  • Endoscopic response: An improvement in the appearance of the intestinal lining as viewed through an endoscope, which is a tool used to examine the inside of the body.
  • Placebo: A substance with no active therapeutic effect, used as a control in testing new drugs.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Standard of Care (SoC): The treatment approach that is accepted by medical experts as the most appropriate and widely used for a specific condition.
  • Randomized: A process in clinical trials where participants are assigned by chance to different treatment groups to reduce bias.
  • Double-blind: A study design where neither the participants nor the researchers know who is receiving the investigational treatment and who is receiving a placebo.

References

  1. http://clinicaltrials.eu/trial/study-on-ve303-for-preventing-recurrent-c-difficile-infection-in-patients/
  2. http://clinicaltrials.eu/trial/study-on-ve202-for-patients-with-mild-to-moderate-ulcerative-colitis/